Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB
[thumbnail of Supplemental Information]
Preview
PDF (Supplemental Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
956kB

Item Type:Article
Title:Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
Creators Name:Kreye, J., Reincke, S.M., Edelburg, S., Jeworowski, L.M., Kornau, H.C., Trimpert, J., Hombach, P., Halbe, S., Nölle, V., Meyer, M., Kattenbach, S., Sánchez-Sendin, E., Schmidt, M.L., Schwarz, T., Rose, R., Krumbholz, A., Merz, S., Adler, J.M., Eschke, K., Abdelgawad, A., Schmitz, D., Sander, L.E., Janssen, U., Corman, V.M. and Prüss, H.
Abstract:The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142 based on its potency and breadth against the VOCs Alpha, Beta, Gamma, and Delta for preclinical development into a therapeutic. CV38-142 showed in vivo efficacy in a Syrian hamster VOC infection model after post-exposure and therapeutic application and revealed a favorable safety profile in a human protein library screen and tissue cross-reactivity study. Although CV38-142 targets the same viral surface as sotrovimab, which maintains activity against Omicron, CV38-142 did not neutralize the Omicron lineages BA.1 and BA.2. These results highlight the contingencies of developing antibody therapeutics in the context of antigenic drift and reinforce the need to develop broadly neutralizing variant-proof antibodies against SARS-CoV-2.
Keywords:Animals, Hamsters
Source:iScience
ISSN:2589-0042
Publisher:Cell Press
Volume:26
Number:4
Page Range:106323
Date:21 April 2023
Official Publication:https://doi.org/10.1016/j.isci.2023.106323
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library